Adaptimmune raises US$42mAs cancer immune therapy specialist Adaptimmunes R&D pipeline has expanded from 9 to 11 candidates and R&D cost rose from US$40.5m to US$63.8m, the company needed more funds. more ➔
Menarini expands into CTC liquid biopsyMenarini-Silicon Biosystems Inc., a wholly owned subsidiary of Bologna-based Menarini Group, has completed the take-over of the Cellsearch Circulating Tumour Cell System from Janssen Diagnostic … more ➔
Astellas to acquire Ogeda SAJapanese pharma major Astellas has announced it will take over private Belgian drug developer Ogeda S.A. for €800m. more ➔
Janssen terminates daratumab development i... Genmab A/S has announced that its CD38-targeting Phase II candidate daratumab did not reach the expected ORR in non-Hodgkins lymphoma patients. Co-developer Janssen has decided to terminate development … more ➔
Biostep Forum: Bioeconomy strategy update...The evaluation of the European bioeconomy strategy will take longer than initially planned. According to information given at the Biostep Forum in Brussels, results won’t be available before next … more ➔
Selvita to cash in €90m in Menarini dealPolish drug developer Selvita has out-licenced its first lead compound to Berlin-Chemie Menarini, a company of the Menarini Group. Ongoing clinical trails with SEL 24 will be conducted … more ➔
EU nations go on blocking GM cropsThe EUs opt-out clause for GM cultivation has missed its goal to accelerate EU market approval of safety-assessed genetically modified crops whilst giving member states the option to opt out from cultivation … more ➔
EMA backs three orphan drugsThree of six new meds to be approved in Europe are orphan drugs and have been backed by the European Medicines Agency (EMA) this month. more ➔
FDA approves Mercks avelumab in MCC Good news for EMD Serono, the US arm of German Merck: Its PD-L1 blocker avelumab is the first drug that received FDA approval to treat the rare skin cancer Merkel Cell Carcinoma (MCC). more ➔
BIO-Europe Spring: Southern growth ambitio...With around 2,500 attendees, Barcelona hosted the most successful BIO Europe Spring conference in the history of the EBDs partnering event. Southern Europe demonstrated its growth ambitions in the … more ➔
